Table 1 Demographics and characteristics of patients with CARDS for more than 50 days on VV-ECMO
Gender | |
Female | 6 (43%) |
Male | 8 (57%) |
Age (years) | 49 (±11) |
BMI (kg/m2) | 33 (±7) |
Comorbidities | |
None | 4 (28%) |
Arterial Hypertension | 5 (36%) |
Diabetes | 4 (29%) |
Immunocompromised | 1 (7%) |
Cardiomyopathy | 1 (7%) |
Othersa | 6 (43%) |
Blood group | |
A | 7 (50%) |
B | 1 (7%) |
O | 6 (43%) |
AB | 0 (0%) |
Treatment before VV-ECMO initiation | |
Dexamethasone | 13 (93%) |
NO inhalation | 10 (71%) |
Neuromuscular blocking agent | 14 (100%) |
Prone position | 14 (100%) |
Organ failures | |
Lowest PaO2/FiO2 ratio before VV-ECMO initiation | 51 (±16) |
SOFA score | 5 (±2) |
Disease course (days) | |
Time from hospital admission to ICU admission | 3 (0—7) |
Time from hospital admission to MV | 6 (2—10) |
Time from ICU admission to MV | 1 (0—4) |
Hospital length-of-stay before VV-ECMO initiation | 11 (8—14) |
ICU length-of-stay before VV-ECMO initiation | 6 (4—8) |
Duration of MV before VV-ECMO initiation | 5 (5—7) |